Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Armistice Capital Is Jumping On Pernix Therapeutics Holdings Inc (PTX)’s Bandwagon, Should You Jump Too?

Page 1 of 2

According to a recent filing with the Securities and Exchange Commission, Steven Boyd‘s Armistice Capital initiated a position in Pernix Therapeutics Holdings Inc (NASDAQ:PTX) by acquiring some 3.4 million shares valued at $18.97 million, according to the current stock price. The holding amasses about 5.7% of the company’s outstanding common stock. So far this year, shares of the $252.10 million specialty pharmaceutical company have slid by more than 40%, a stark contrast to almost 22% gains for the Specialty & Generic drug manufacturing industry.


Professional money managers have been taking an increased interest in Pernix Therapeutics Holdings Inc (NASDAQ:PTX). Among the hedge funds that we track, 19 had invested a total of $124.90 million in the company at the end of March, as compared to 13 funds with $113.96 million at the end of the previous quarter. Interestingly, though total ownership jumped by nearly 50%, the aggregate capital held by the funds actually declined slightly when we factor out the appreciation of the stock during first quarter, which certainly sent some mixed signals as far as hedge funds’ sentiment.

Steven Boyd
Steven Boyd
Armistice Capital

Most investors can’t outperform the stock market by individually picking stocks because stock returns aren’t evenly distributed. A randomly picked stock has only a 35% to 45% chance (depending on the investment horizon) to outperform the market. There are a few exceptions, one of which is when it comes to purchases made by corporate insiders. Academic research has shown that certain insider purchases historically outperformed the market by an average of seven percentage points per year. This effect is more pronounced in small-cap stocks. Another exception is the small-cap stock picks of hedge funds. Our research has shown that the 15 most popular small-cap stocks among hedge funds outperformed the market by nearly a percentage point per month between 1999 and 2012. We have been forward testing the performance of these stock picks since the end of August 2012 and they have returned more than 135% over the ensuing 34 months, outperforming the S&P 500 Index by nearly 80 percentage points (read the details here). The trick is focusing only on the best small-cap stock picks of funds, not their large-cap stock picks which are extensively covered by analysts and followed by almost everybody.

Insider trading, especially insider purchases can provide extremely useful information related to the company’s future prospects, and that is why we keep a close eye on such transactions. As far as Pernix Therapeutics Holdings Inc (NASDAQ:PTX) is concerned, Douglas Drysdale, the company’s CEO, and Sanjay Patel, who is Pernix’s CFO, bought 16,000 and 2,000 shares respectively last month, while no insider sales have been registered this year.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!